Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Best Cell phone Brands for Tech Lovers - 2The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- 3People are getting their news from AI – and it’s altering their views
- 4Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- 5A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- 7 Moves toward a Sound and Dynamic Way of life
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- I'm an 83-year-old yoga instructor. I'm not your typical grandma — I still work to feel fulfilled and supplement my Social Security.
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- Moon memorial: Artemis 2 astronauts name lunar 'bright spot' after mission commander's late wife
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- UPM Adhesive Materials plans new facility near New Delhi, India
